Shares of Relmada Therapeutics (RLMD) rose after Piper Sandler initiated coverage with an Overweight rating, highlighting the potential of its lead cancer candi
Relmada Therapeutics (RLMD) Gains on Positive Analyst Coverage
Mar 24, 2026
![i’m-nervous,-too!-[part-2]](https://10xwealthreport.com/wp-content/uploads/2026/03/177042-im-nervous-too-part-2-1568x784.jpg)
